ClinicalTrials.gg
RecruitingNCT07942168SARCOGYNUpdated Nov 17, 2026

Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine Leiomyosarcoma

A Phase 2 interventional study of Doxorubicin and Doxorubicin in Leiomyosarcoma and Uterine Leiomyosarcoma, sponsored by Blokhin's Russian Cancer Research Center. Recruiting at 1 site in Russia. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Blokhin's Russian Cancer Research Center · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 8 months after the study started (first participant enrolled Jan 2023, registered Oct 2026).
  • Started Jan 2023; still recruiting 3 years 9 months later.
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to learn whether adding dacarbazine to doxorubicin works better than doxorubicin alone as the first drug treatment for women with uterine leiomyosarcoma that is metastatic or has come back after surgery. A total of 100 participants will be randomly assigned to receive either doxorubicin alone or doxorubicin plus dacarbazine for up to 6 cycles of 21 days each. Researchers will compare how many participants are alive without disease progression 1 year after the start of treatment.

Read the detailed description

Leiomyosarcoma (LMS) represents 10-20% of soft-tissue sarcomas and has a poor prognosis in advanced stages. Retrospective multicenter data suggest that the doxorubicin plus dacarbazine combination improves progression-free survival (9.2 vs. 4.8 months) and response rates (30.9% vs. 25.6%) over doxorubicin alone in the advanced disease setting; however, this has never been investigated in randomized trials. This single-center, open-label trial compares doxorubicin plus dacarbazine with doxorubicin alone as first-line systemic therapy in patients with metastatic uterine leiomyosarcoma or with disease recurrence after prior surgical treatment.

02

Conditions studied

  • Leiomyosarcoma
  • Uterine Leiomyosarcoma

Browse trials for

Keywords

  • Doxorubicin
  • Dacarbazine
  • firtst-line chemotherapy
  • metastatic leiomyosarcoma
  • uterine sarcoma
03

In context

Leiomyosarcoma

178 studies on the registry are indexed under Leiomyosarcoma; 36 are open to participants now.

This study's planned enrollment of 100 is above the median of 55 across 152 interventional studies indexed under Leiomyosarcoma.

Browse Leiomyosarcoma studies →

Lead sponsor

Blokhin's Russian Cancer Research Center is the lead sponsor of 34 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

  1. Morphologically verified uterine leiomyosarcoma
  2. Age 18 to 70 years
  3. (ECOG) performance status 0-2
  4. disease at diagnosis, or disease recurrence after prior surgical treatment for localized disease
  5. No prior systemic anticancer therapy
  6. No to doxorubicin and dacarbazine
  7. Metastatic or recurrent disease confirmed by contrast-enhanced computed tomography (CT) of the chest, abdomen and pelvis (contrast-enhanced magnetic resonance imaging (MRI) of the pelvis is allowed)
  8. on CT or MRI prior to randomization
  9. Consent to treatment at N.N. Blokhin National Medical Research Center of Oncology
  10. Consent to the proposed chemotherapy regimen
  11. Adequate bone marrow function: ≥1.5×10⁹/L, ≥100×10⁹/L
  12. Adequate liver function: ≤1.5 × (ULN), (AST) and alanine aminotransferase (ALT) ≤3 × ULN
  13. Adequate cardiac function: satisfactory left ventricular systolic function
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Doxorubicin

    Participants receive 6 cycles of Doxorubicin. Each cycle is 21 days.

    Drug: Doxorubicin

  • Experimental
    Doxorubicin+Dacarbazine

    Participants receive 6 cycles of Doxorubicin+Dacarbazine. Each cycle is 21 days.

    Drug: Doxorubicin · Drug: dacarbazine

Interventions

  • Doxorubicin 75 mg/m² IV infusion, Day 1, Q3W for 6 cycles in first line

    Also known as: Adriamycin

  • Doxorubicin 15 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line

    Also known as: Adriamycin

  • Dacarbazine 187.5 mg/m²/day IV 24-h continuous infusion, Days 1-4, Q3W for 6 cycles in first line

    Also known as: DTIC

06

What researchers measure

Primary outcomes

  1. 1-year progression-free survival (PFS)

    1-year PFS is defined as time from enrollment to disease progression or relapse or death due to any cause at 1 year (12-month PFS)

    Time frame: Time from enrollment to disease progression or relapse or death due to any cause, or data cut-off date at 1 year, whichever occured first (up to ~12 months)

Secondary outcomes

  1. Overall Survival

    OS is defined as time from enrollment to death due to any cause

    Time frame: Time from enrollment to death due to any cause, or data cut-off date, whichever occurred first (up to ~36 months)

  2. Objective Response Rate

    Proportion of patients achieving complete or partial response per RECIST 1.1

    Time frame: After 3 cycles ( week 9) and after 6 cycles (week 18); each cycle is 21 days

  3. incidence of Adverse events

    Proportion of patients experiencing adverse events in each treatment arm

    Time frame: During 6 cycles of treatment( each cucle is 21 days), up to 18 weeks

07

Study locations

1 of 1 sites recruiting
  • Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO)
    Moscow, Russia
    Recruiting
    • Alexander Anokhin, PhD · Contactanokhinaleks@mail.ru · +7-915-518-85-00
    • Alexey Rumyantsev, PhD · Contacta.rumyantsev@ronc.ru · +7-499-324-10-87
    • Alexander Anokhin, PhD · Principal investigator
    • Alexey Rumyantsev, PhD · Sub investigator
08

References and documents

Publications

  • D'Ambrosio L, Touati N, Blay JY, Grignani G, Flippot R, Czarnecka AM, Piperno-Neumann S, Martin-Broto J, Sanfilippo R, Katz D, Duffaud F, Vincenzi B, Stark DP, Mazzeo F, Tuchscherer A, Chevreau C, Sherriff J, Estival A, Litiere S, Sents W, Ray-Coquard I, Tolomeo F, Le Cesne A, Rutkowski P, Stacchiotti S, Kasper B, Gelderblom H, Gronchi A; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cancer. 2020 Jun 1;126(11):2637-2647. doi: 10.1002/cncr.32795. Epub 2020 Mar 4. PubMed 32129883 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared because the informed consent form does not provide for sharing of data outside the research team.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2027, 48 months after the start.

Of 39 non-industry phase 2 interventional studies under Leiomyosarcoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 80. This study's planned 48 months is below that.

Counting every sponsor, half of 42 studies reached it within 62 months; a quarter within 38 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2026
First posted
Nov 17, 2026
StartActual
Jan 24, 2023
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942168
Lead sponsor
Blokhin's Russian Cancer Research Center
Responsible party
Alexander Anokhin (medical oncologist at of the Chemotherapy Department No 4, Blokhin's Russian Cancer Research Center) — Principal investigator
First posted
Nov 17, 2026
Start date
Jan 24, 2023
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Alexander Anokhin, PhD
Contact
anokhinaleks@mail.ru
+7-915-518-85-00

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dacarbazine

Start the discussion